Analytical Data
-
基因名
Cathepsin K
- Application
-
别名
CTS-K; CTS02; CTSO; CTSO1; CTSO2; PKND; PYCD; Pycnodysostosis; Cathepsin O; Cathepsin X
-
种属
Pig
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q9GLE3
-
表达区间
Lys90~Ala318
-
分子量
55kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cathepsin K is a lysosomal cysteine protease primarily expressed in osteoclasts, playing a crucial role in bone resorption and remodeling. It has garnered significant attention in biomedical research due to its implications in various diseases, including osteoporosis, arthritis, and certain forms of cancer. The enzyme's ability to degrade collagen and other extracellular matrix components makes it vital in the pathological processes of bone degradation and tissue remodeling. Researchers have focused on producing recombinant Cathepsin K to facilitate in vitro studies, enabling a better understanding of its enzymatic mechanisms and substrate specificity. The recombinant protein provides a reliable and abundant source for screening potential inhibitors that could serve as therapeutic agents for conditions characterized by excessive bone resorption. Additionally, structural studies of recombinant Cathepsin K have offered insights into its active site and the conformational changes associated with its catalytic activity. This research is critical for developing targeted inhibitors that can effectively modulate Cathepsin K activity, ultimately leading to novel treatment strategies for bone-related disorders and improving patient outcomes. As such, the study of recombinant Cathepsin K not only enhances our understanding of its biological functions but also paves the way for innovative therapeutic interventions in diseases where dysregulation of bone metabolism is a key feature.












